Beyond HRD Status : Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
Kjeldsen, Maj K. ; Jørgensen, Morten ; Grønseth, Dina Sofie B. ; Schønemann-Lund, Martin ; Nyvang, Gitte Bettina ; Haslund, Charlotte Aaquist ; Knudsen, Anja Oer ; Motavaf, Anne Krejbjerg ; Malander, Susanne LU
and Anttila, Maarit
, et al.
(2024)
In Cancer Research Communications
4(12).
p.3190-3200
- Abstract
SIGNIFICANCE: The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing precision oncology in future clinical practice.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/36c5746e-ff61-4442-b8e6-25145f4527d3
- author
- Kjeldsen, Maj K.
; Jørgensen, Morten
; Grønseth, Dina Sofie B.
; Schønemann-Lund, Martin
; Nyvang, Gitte Bettina
; Haslund, Charlotte Aaquist
; Knudsen, Anja Oer
; Motavaf, Anne Krejbjerg
; Malander, Susanne
LU
and Anttila, Maarit
, et al. (More)
- Kjeldsen, Maj K.
; Jørgensen, Morten
; Grønseth, Dina Sofie B.
; Schønemann-Lund, Martin
; Nyvang, Gitte Bettina
; Haslund, Charlotte Aaquist
; Knudsen, Anja Oer
; Motavaf, Anne Krejbjerg
; Malander, Susanne
LU
; Anttila, Maarit
; Lindahl, Gabriel
; Mäenpää, Johanna
; Dimoula, Maria
; Werner, Theresa L.
; Iversen, Trine Zeeberg
; Hietanen, Sakari
; Fokdal, Lars
; Dahlstrand, Hanna
; Bjørge, Line
; Birrer, Michael J.
; Mirza, Mansoor R.
and Rossing, Maria
(Less)
- organization
- publishing date
- 2024-12
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cancer Research Communications
- volume
- 4
- issue
- 12
- pages
- 11 pages
- external identifiers
-
- scopus:85214054632
- pmid:39591206
- ISSN
- 2767-9764
- DOI
- 10.1158/2767-9764.CRC-24-0294
- language
- English
- LU publication?
- yes
- id
- 36c5746e-ff61-4442-b8e6-25145f4527d3
- date added to LUP
- 2025-02-26 11:06:33
- date last changed
- 2025-06-04 19:14:52
@article{36c5746e-ff61-4442-b8e6-25145f4527d3,
abstract = {{<p>SIGNIFICANCE: The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing precision oncology in future clinical practice.</p>}},
author = {{Kjeldsen, Maj K. and Jørgensen, Morten and Grønseth, Dina Sofie B. and Schønemann-Lund, Martin and Nyvang, Gitte Bettina and Haslund, Charlotte Aaquist and Knudsen, Anja Oer and Motavaf, Anne Krejbjerg and Malander, Susanne and Anttila, Maarit and Lindahl, Gabriel and Mäenpää, Johanna and Dimoula, Maria and Werner, Theresa L. and Iversen, Trine Zeeberg and Hietanen, Sakari and Fokdal, Lars and Dahlstrand, Hanna and Bjørge, Line and Birrer, Michael J. and Mirza, Mansoor R. and Rossing, Maria}},
issn = {{2767-9764}},
language = {{eng}},
number = {{12}},
pages = {{3190--3200}},
series = {{Cancer Research Communications}},
title = {{Beyond HRD Status : Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer}},
url = {{http://dx.doi.org/10.1158/2767-9764.CRC-24-0294}},
doi = {{10.1158/2767-9764.CRC-24-0294}},
volume = {{4}},
year = {{2024}},
}